Formycon Reports Positive Phase III Data On Ustekinumab

Company Is Looking For Marketing Partner On Stelara Biosimilar By Year End

Aug 17 2022

Formycon has celebrated the latest results for its FYB202 ustekinumab candidate • Source: Shutterstock